Orca Bio

United States · Pharmaceuticals

Orca Bio is a clinical biotechnology company based in Menlo Park, California, specializing in high-precision allogeneic T-cell immunotherapies. The company focuses on treating serious blood cancers, genetic blood disorders, and autoimmune diseases. Orca Bio aims to enhance the traditional allogeneic stem cell transplant process by developing purified cell therapies that improve patient survival rates and reduce treatment-related toxicities, such as chronic graft-versus-host disease (GvHD). The company's product pipeline includes two main investigational candidates: Orca-T, designed for hematological malignancies and currently in a pivotal Phase 3 clinical trial, and Orca-Q, which aims to expand treatment options without requiring a fully matched donor. Orca Bio operates a state-of-the-art cGMP manufacturing facility in Sacramento, California, ensuring high-quality production of its therapies. The company targets patients with high-risk blood cancers and autoimmune diseases, working closely with healthcare providers and specialized treatment centers to improve treatment outcomes.